Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a research note issued on Tuesday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Performance

NYSE:OGEN opened at $0.33 on Tuesday. The firm has a market cap of $4.07 million, a P/E ratio of -0.05 and a beta of 0.40. Oragenics has a fifty-two week low of $0.25 and a fifty-two week high of $6.42. The firm has a 50-day simple moving average of $0.34 and a two-hundred day simple moving average of $0.65.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.